Comments
Loading...

Blueprint Medicines

BPMCNASDAQ
Logo brought to you by Benzinga Data
$89.33
2.823.26%
At Close: -
$89.33
00.00%
After Hours: 4:08 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$168.00
Lowest Price Target1
$43.00
Consensus Price Target1
$110.04

Blueprint Medicines (NASDAQ:BPMC) Stock, Analyst Ratings, Price Targets, Forecasts

Blueprint Medicines Corp has a consensus price target of $110.04 based on the ratings of 23 analysts. The high is $168 issued by Goldman Sachs on May 6, 2024. The low is $43 issued by SVB Leerink on June 5, 2023. The 3 most-recent analyst ratings were released by Needham, Guggenheim, and Baird on August 5, 2024, August 2, 2024, and August 2, 2024, respectively. With an average price target of $132.67 between Needham, Guggenheim, and Baird, there's an implied 48.51% upside for Blueprint Medicines Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Apr
1
3
1
May
0
0
0
0
Jun
1
2
Jul
1
Aug
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.2
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Needham
Guggenheim
Baird
Barclays
Morgan Stanley

1calculated from analyst ratings

Analyst Ratings for Blueprint Medicines

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Blueprint Medicines (BPMC) stock?

A

The latest price target for Blueprint Medicines (NASDAQ:BPMC) was reported by Needham on August 5, 2024. The analyst firm set a price target for $133.00 expecting BPMC to rise to within 12 months (a possible 48.89% upside). 37 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Blueprint Medicines (BPMC)?

A

The latest analyst rating for Blueprint Medicines (NASDAQ:BPMC) was provided by Needham, and Blueprint Medicines maintained their buy rating.

Q

When was the last upgrade for Blueprint Medicines (BPMC)?

A

The last upgrade for Blueprint Medicines Corp happened on May 6, 2024 when Leerink Partners raised their price target to $97. Leerink Partners previously had an underperform for Blueprint Medicines Corp.

Q

When was the last downgrade for Blueprint Medicines (BPMC)?

A

The last downgrade for Blueprint Medicines Corp happened on June 5, 2023 when SVB Leerink changed their price target from $48 to $43 for Blueprint Medicines Corp.

Q

When is the next analyst rating going to be posted or updated for Blueprint Medicines (BPMC)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Blueprint Medicines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Blueprint Medicines was filed on August 5, 2024 so you should expect the next rating to be made available sometime around August 5, 2025.

Q

Is the Analyst Rating Blueprint Medicines (BPMC) correct?

A

While ratings are subjective and will change, the latest Blueprint Medicines (BPMC) rating was a maintained with a price target of $130.00 to $133.00. The current price Blueprint Medicines (BPMC) is trading at is $89.33, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch